Drug Profile

VTP 1000

Alternative Names: VTP-1000

Latest Information Update: 01 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Oxford
Developer Barinthus Biotherapeutics
Class Immunotherapies; Vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Coeliac disease

Most Recent Events

24 Sep 2024 Phase-I clinical trials in Coeliac disease (In adults) in USA (IM) (NCT06310291)
13 May 2024 Barinthus Biotherapeutics plans a phase I GLU001 trial for Coeliac disease in the third quarter of 2024
13 May 2024 US FDA and Australian regulatory authorities approves IND clearance for VTP 1000 in Coeliac disease

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com